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M A J O R A R T I C L E
Pathologic Changes in Mice Induced by Subtilase
Cytotoxin, a Potent New Escherichia coli AB5 Toxin
That Targets the Endoplasmic Reticulum
Hui Wang, James C. Paton, and Adrienne W. Paton
School of Molecular and Biomedical Science, University of Adelaide, Australia
Subtilase cytotoxin (SubAB) is the prototype of a recently discovered AB5 cytotoxin family produced by certain
strains of Shiga toxigenic Escherichia coli (STEC). The catalytic A subunit is a highly specific subtilase-like
serine protease that cleaves the endoplasmic reticulum chaperone BiP. The toxin is lethal for mice, but the
pathology it induces is poorly understood. Here, we show that intraperitoneal injection of SubAB causes
microangiopathic hemolytic anemia, thrombocytopenia, and renal impairment in mice—characteristics typical
of Shiga toxin–induced hemolytic uremic syndrome. SubAB caused extensive microvascular thrombosis and
other histologic damage in the brain, kidneys, and liver, as well as dramatic splenic atrophy. Peripheral blood
leukocyte levels were increased at 24 h; there was also significant neutrophil infiltration in the liver, kidneys,
and spleen and toxin-induced apoptosis at these sites. These findings raise the possibility that SubAB directly
contributes to pathology in humans infected with strains of STEC that produce both Shiga toxin and SubAB.
Shiga toxigenic Escherichia coli (STEC) produce AB5
toxins belonging to the Shiga toxin (Stx) family [1, 2].
Their pentameric B subunits bind glycolipid receptors
on target cells. This is followed by internalization of
the toxin, retrograde transport to the endoplasmic re-
ticulum (ER), translocation of the A subunit into the
cytoplasm, and inhibition of protein synthesis. STEC
cause severe gastrointestinal disease in humans that may
result in hemorrhagic colitis (HC) and hemolytic
uremic syndrome (HUS; a triad of microangiopathic
hemolytic anemia, thrombocytopenia, and renal fail-
ure) [1, 2]. The pathology of severe STEC disease is
considered to be directly attributable to Stx. STEC col-
onize the gut, and Stx released into the lumen is trans-
Received 5 February 2007; accepted 8 May 2007; electronically published 22
August 2007.
Potential conflicts of interest: none reported.
Financial support: National Health and Medical Research Council of Australia
(program grant 284214); National Institutes of Health (grant RAI068715A).
Reprints or correspondence: Dr. Adrienne Paton, School of Molecular and
Biomedical Science, University of Adelaide, S.A., 5005, Australia (adrienne
.paton@adelaide.edu.au).
The Journal of Infectious Diseases 2007; 196:1093–101
 2007 by the Infectious Diseases Society of America. All rights reserved.
0022-1899/2007/19607-0023$15.00
DOI: 10.1086/521364
located across the intestinal epithelium and absorbed
into the circulation. It then targets tissues expressing
the receptor Gb3, which in humans is found in highest
concentrations in renal tubular epithelial cells and in
microvascular endothelial cells, particularly in the kid-
neys, gut, and brain. Stx-mediated damage at these sites
is consistent with the pathology of HUS. Microvascular
and concomitant ischemic damage to the intestinal wall
also accounts for the severe bloody diarrhea associated
with HC [1, 2].
There is increasing evidence that STEC strains vary
in their capacity to cause serious disease. A contributing
factor may be the amount or subtype of Stx produced.
However, molecular investigations have identified po-
tential accessory virulence factors encoded on patho-
genicity islands or plasmids [1, 2]. One such factor is
the capacity to produce attaching/effacing lesions on
enterocytes, encoded by the locus for enterocyte ef-
facement (LEE) [2]. LEE-positive STEC cause most
cases of HUS, particularly in outbreak settings [1, 2].
However, in 1998 we investigated a small outbreak of
HUS caused by an O113:H21 STEC that produced Stx2
but was LEE negative [3]. Despite the absence of LEE,
O113:H21 STEC are highly virulent, causing disease at
the extreme end of the clinical spectrum. O113:H21
1094 • JID 2007:196 (1 October) • Wang et al.
was among the first STEC serotypes to be causally associated
with HUS [4]. The potency of Stx produced by the isolate was
comparable to that of typical LEE-positive, HUS-associated
strains [3]. We therefore postulated that O113:H21 strains pro-
duce an additional cytotoxin capable of augmenting the effects
of Stx2 or causing additional pathology. This led to the dis-
covery of subtilase cytotoxin (SubAB), the prototype of a new
family of AB5 toxins, produced by several STEC serotypes [5,
6]. SubAB is more toxic than Stx for Vero cells in vitro and is
lethal for mice. It was named “subtilase cytotoxin” because its
A subunit (SubA) shares sequence homology with a subtilase-
like serine protease of Bacillus anthracis [5]. Subtilases are found
in a wide variety of microorganisms, but none had previously
been shown to be cytotoxic [7]. Mutagenesis of a critical Ser
residue in SubA abolished toxicity, which indicates that serine
protease activity is central to its mechanism of action [5]. The
B subunit is related to putative exported proteins from Yersinia
pestis and Salmonella typhi and binds to glycolipid receptors
on target cells [5].
Recently, we reported that the extreme cytotoxicity of SubAB
for eukaryotic cells is due to a specific single-site cleavage of
the ER chaperone BiP [8]. Structural analysis of SubA revealed
an unusually deep active site cleft, which accounted for this
exquisite substrate specificity [8]. BiP is a master regulator of
ER function [9], and its cleavage represented a previously un-
known cytotoxic mechanism. Notwithstanding the extraordi-
nary cytotoxicity of SubAB, its role in the pathogenesis of STEC
disease in humans is uncertain. In the present study, we have
examined the effects of the administration of purified SubAB
to mice. We have found evidence of histopathologic, biochem-
ical, and hematologic changes with striking similarities to those
seen in humans with HUS.
MATERIALS AND METHODS
Toxin purification. SubAB and its nontoxic derivative
SubAA272B were purified as described elsewhere [5, 10].
Mice. Animal experimentation was approved by the Ani-
mal Ethics Committee of the University of Adelaide. Male
BALB/c mice, 5–6 weeks old, were injected intraperitoneally
(ip) with 5 mg of purified SubAB or SubAA272B (dissolved in
200 mL of PBS). Control mice received 200 mL of PBS.
Biochemical and hematologic analysis. At various times
after SubAB injection, mice were anesthetized with Halothane
(Veterinary Companies of Australia). Blood samples were ob-
tained via cardiac puncture and collected into either lithium
heparin or EDTA tubes. Blood urea, alanine aminotransferase
(ALT), aspartate aminotransferase (AST), creatine phosphoki-
nase (CPK), and lactate dehydrogenase (LDH) levels were as-
sayed at Gribbles Veterinary Pathology Laboratory (Adelaide,
Australia). Blood glucose levels were measured using a Medi-
sense Optium electrode (Abbott Laboratories). Glucose and
protein concentrations in urine were estimated using UriScan
dipsticks (YD Diagnostics).
For platelet counts, blood was diluted 1:100 in PBS, and
platelets were enumerated by light microscopy. For white blood
cell counts, blood in EDTA was diluted 1:20 in acetic blue
solution, and cells were counted. Blood smears from 5 mL of
blood in EDTA were fixed in 100% methanol for 2 min, stained
in Giemsa stain for 4 min, and examined by light microscopy
(Axiophot) with an Image Capturing Camera (FUJIX HC-1000,
3CCD; FUJIFILM); digital images were captured and processed
using Photograb SP-MA software (version 2.0; FUJIFILM).
Hemolysis and red blood cell (RBC) fragility. For the de-
tection of intravascular hemolysis, plasma hemoglobin con-
centrations were measured at 6, 24, 48, and 72 h after SubAB
injection. Heparinized cardiac blood was diluted 1:100 in iso-
tonic saline and centrifuged at 1500 g at 4C for 10 min, and
the A540 of the supernatant was measured.
To compare RBC fragility, resistance to hypotonic shock was
measured. Heparinized cardiac blood was diluted 1:100 in sa-
line solutions ranging from 2 to 9 g of NaCl per liter. After 30
min at room temperature, suspensions were centrifuged, and
the supernatant A540 was measured.
Histopathologic analysis. After blood sampling, brain,
heart, liver, spleen, and kidneys were removed and fixed in 4%
formaldehyde overnight at 4C, embedded in paraffin, sec-
tioned, stained with hematoxylin-eosin (HE), and examined by
light microscopy.
Neutrophil infiltration. Organs—including brain, liver,
spleen, kidneys, and ileum—were removed 24 and 48 h after
SubAB injection and embedded in OCT Tissue-Tek (Sakura),
snap frozen in isopentane cooled with liquid nitrogen, and stored
at 80C. Serial 6-mm sections were cut in a cryostat, air dried,
and stored dehydrated at 80C. Cryopreserved sections were
fixed in 4% paraformaldehyde for 20 min and washed 3 times
with PBS. Sections were then incubated in the dark for 1 h at
room temperature with 50 mL of 50 mg/mL monoclonal rat anti–
mouse Ly-6G (specific for granulocyte-restricted cell surface pro-
tein [mainly neutrophils]; PharMingen 551459; BD Biosciences)
followed by 50 mL of fluorescein isothiocyanate–conjugated don-
key anti–rat immunoglobulin (diluted 1:50; Jackson Immuno-
Research). Both antibodies were diluted in 10% heat-inactivated
fetal calf serum in PBS. Three PBS washes were performed after
each incubation, and slides were examined by fluorescence
microscopy.
TUNEL labeling of tissue sections. Apoptosis was assessed
by TUNEL labeling using an In Situ Cell Death Detection Kit
(Roche) with tetramethylrhodamine red–conjugated nucleo-
tides and terminal deoxynucleotidyl transferase. Cryopreserved
sections were fixed in 4% paraformaldehyde for 20 min and
permeabilized with 0.1% Triton X-100 and 0.1% sodium citrate
in PBS for 2 min at room temperature. Sections were washed
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Figure 1. Effect of subtilase cytotoxin (SubAB) on blood chemistry.
Blood was collected from control or treated mice at the indicated times
after the intraperitoneal injection of 5 mg of SubAB or 5 mg of nontoxic
SubAA272B ( for each group). Differences between control and toxin-np 4
treated mice were analyzed using Student’s t test: * ; ** .P ! .05 P ! .01
ALT, alanine aminotransferase; AST, aspartate aminotransferase; CPK,
creatine phosphokinase; LDH, lactate dehydrogenase.
twice with PBS before and after permeabilization. Fifty mi-
croliters of TUNEL reagent was added, and sections were in-
cubated in a humidified atmosphere in the dark for 1 h, washed
3 times in PBS, and analyzed by fluorescence microscopy.
Fluorescence microscopy. Fluorescent-labeled tissue sec-
tions were mounted in 10 mL of 30% glycerol and analyzed by
fluorescence microscopy (AX 70; Olympus); digital images were
taken with a Precision Digital Imaging System (Digital Optics).
For quantitative analysis, Ly-6G– or TUNEL-positive cells were
counted in at least 3 high- or low-power fields.
Statistical analysis. Statistical analysis was performed us-
ing Prism software (version 3.03; GraphPad). Data are pre-
sented as mean  SE, and differences were analyzed using
Student’s t test.
RESULTS
Biochemical analysis. Because the tissues targeted by SubAB
in vivo have not been determined, blood collected 6, 24, 48
and 72 h after the ip injection of 5 mg of SubAB was analyzed
for biochemical markers of specific organ damage. We observed
progressive increases in urea, ALT, AST, CPK, and LDH levels
in toxin-treated mice (figure 1). For urea levels, the elevation
relative to levels of control mice was statistically significant as
early as 24 h after injection, whereas for AST, CPK, and LDH
levels, statistically significant increases were evident at 48 h.
Levels of ALT in blood at 72 h after injection were also elevated
but did not reach statistical significance. The elevated urea levels
suggest that renal function is impaired within 24 h and that,
by 48 h, there is significant damage to other organs, including
the liver, as indicated by elevated AST (and possibly ALT) levels.
The significant elevation in CPK levels at 48 h is suggestive of
myocardial injury, whereas elevated LDH and AST levels may
also indicate more generalized toxicity, perhaps including he-
molysis. SubAB treatment also caused significant hypoglycemia,
with blood glucose levels dropping from mmol/L6.95 0.21
before injection to and mmol/L at 24 and3.55 0.35 2.6 0
48 h after injection, respectively ( vs. control in bothP ! .05
cases). Analysis of urine from toxin-treated mice did not reveal
evidence of glucosuria either before or up to 48 h after injection.
However, SubAB induced significant proteinuria; urinary pro-
tein levels were in the range of 0.3–1 g/L for all mice at both
24 and 48 h after injection, compared with !0.1 g/L before
injection.
Histopathologic analysis. Organs—including brain, heart,
liver, kidney, and spleen—were subjected to routine histologic
examination (HE staining) at 24, 48, and 72 h after SubAB
injection. Although there was no obvious damage to cardiac
tissue, significant pathologic changes were found in brain, liver,
kidney, and spleen (figures 2 and 3). Microvascular thrombosis
appeared in the cerebrum (result not shown), brain stem, and
cerebellum as early as 24 h after injection (figure 2B and 2E).
At 72 h, microvascular thrombosis was more widespread, and
hemorrhagic foci were found in the brain stem and cerebellum
(figure 2C and 2F). Such damage to the brain stem is the likely
cause of the sudden death typically observed in mice 3–4 days
after the administration of this dose of toxin. The lesions in
the cerebellum might also explain the ataxia and uncoordinated
movement typically observed immediately before death.
Renal glomeruli were congested from 24 h after SubAB in-
jection, and, at 72 h, some of them exhibited extensive mi-
crothrombotic angiopathy and necrotic thrombosis. Renal tu-
1096 • JID 2007:196 (1 October) • Wang et al.
Figure 2. Hematoxylin-eosin (HE)–stained tissue sections of brain stem, cerebellum, kidney, and liver from control and subtilase cytotoxin (SubAB)–
treated mice. Extensive microthrombi are evident in the medulla oblongata and cerebellar cortex at both 24 and 72 h after toxin treatment (small
arrows in panels B, C, and E), with hemorrhagic foci present at 72 h (large arrows in panels C and F). The renal cortex also contained microthrombi
(small arrows) and interstitial hemorrhages (small arrowheads), and glomeruli were congested (open arrowheads) at 24 and 72 h after SubAB injection
(H and I). At 72 h, capillary lumina were frequently obstructed because of microthrombotic angiopathy (large arrowhead in panel I) and necrotic
thrombosis (large arrow in panel I). Renal tubular epithelial cells were also swollen with diminished lumen diameter, and many were undergoing
necrotic change (H and I). Hepatocytes were swollen, and there were localized necrotic foci (circled) at 24 h after SubAB injection. Extensive microthrombi
and hemorrhagic foci were found at 72 h (large arrows) (K and L). In an additional experiment, liver and kidney tissue was examined 48 h after
treatment with either SubAB (N and Q) or 5 mg of nontoxic SubAA272B (O and R). Although pathologic findings for the active toxin-treated samples
were similar to those observed above, sections from SubAA272B-treated mice were indistinguishable from those from untreated controls (M and P).
Scale bar, 0.1 mm.
bules showed extensive epithelial swelling, with decreased
lumen space and generalized necrotic changes. Extensive in-
terstitial hemorrhage was seen in the renal cortex from 24 h
after SubAB injection (figure 2H and 2I).
In the liver, hepatocytes were swollen with decreased sinu-
soidal spaces, and widely distributed necrotic foci were seen as
early as 24 h. Extensive microthrombi and hemorrhagic foci
were found at 72 h (figure 2K and 2L).
Macroscopically, there was a dramatic reduction in the size
of the spleen, which by 72 h had diminished to only one third
Subtilase Cytotoxin-Induced Pathology • JID 2007:196 (1 October) • 1097
Figure 3. Hematoxylin-eosin (HE)–stained spleen sections from control and subtilase cytotoxin (SubAB)–treated mice at low-power (top panels) and
high-power (bottom panels) magnifications. B–D, F–H, Extensive leukocyte redistribution after SubAB injection, compared with normal control spleen
tissue (A and E). Leukocytes disappeared from white pulp and infiltrated the red pulp from 24 h after injection. A–D, Significant and progressive
decrease in overall size of the spleen after SubAB injection. In an additional experiment, spleens were examined 48 h after treatment with either
SubAB (J) or 5 mg of nontoxic SubAA272B (K), with the latter being indistinguishable from the untreated control (I). Scale bars, 0.1 mm.
Figure 4. Giemsa-stained blood smears. A and B, Control mouse. C
and D, Mouse 48 h after subtilase cytotoxin (SubAB) injection. Normal
erythrocytes (R), platelets (P), neutrophils (N), and lymphocytes (L) are
shown in panels A and B. In panels C and D, platelet nos. were diminished,
some of the erythrocytes were fragmented (arrowheads), and leukocytes
exhibited necrotic (black arrows) or apoptotic (white arrows) changes.
Scale bar, 0.01 mm.
its normal size (figure 3A–3D), suggesting extensive splenic
necrosis. Microscopically, there was marked leukocyte redistri-
bution; leukocytes disappeared from white pulp and infiltrated
the red pulp from 24 h after injection (figure 3E–3H).
Hematologic findings. Examination of Giemsa-stained
blood smears (figure 4) indicated that, by 48 h after injection,
many of the erythrocytes were fragmented. Platelets were sig-
nificantly decreased in number, and leukocytes (mainly neu-
trophils and lymphocytes) appeared to be apoptotic or necrotic.
Measurement of free hemoglobin revealed evidence of intra-
vascular hemolysis in 1 of 3 mice tested at 48 h and in 3 of 4
mice tested at 72 h (figure 5A). However, erythrocyte osmotic
fragility was unaffected by toxin treatment (data not shown),
which suggests that intravascular hemolysis was a consequence
of physical damage due to microangiopathy rather than a direct
effect of the toxin on the erythrocyte membrane.
SubAB injection induced a dramatic decrease in the numbers
of platelets in peripheral blood (figure 5B). Thrombocytopenia
was statistically significant within 6 h of injection, and, by 72
h, platelet counts were !35% of those in normal control mice.
SubAB also induced a significant increase in peripheral blood
leukocytes at 24 h (figure 5C).
Neutrophil infiltration. Neutrophil infiltration was ex-
amined in brain, liver, spleen, kidneys, and ileum. Significant
infiltration was seen in liver tissue at 24 h after SubAB injection
and was even more obvious at 48 h (figure 6A). Mean numbers
of Ly-6G–positive cells per low-power field had increased 2.9-
and 7.7-fold, respectively, at these time points (figure 6B)
( in both cases). In the spleen, neutrophil infiltrationP ! .01
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Figure 5. Effect of subtilase cytotoxin (SubAB) on plasma free he-
moglobin, platelet, and total leukocyte counts. Blood was collected from
control mice and at various times after injection with 5 mg of SubAB.
Blood was tested for free hemoglobin (OD570 nm) (A) and counted for
platelets (B) and total leukocytes (C). In panel A, data are shown for
each mouse; data for panels B and C are mean  SE ( ) for eachnp 4
group. Panels B and C also show data for mice treated with 5 mg of
nontoxic SubAA272B (hatched bars). Differences between control and toxin-
treated mice were analyzed using Student’s t test. * ; ** .P ! .05 P ! .01
started from the marginal zone of the white pulp at 24 h and
extended into the white pulp by 48 h (figure 6A). At this time,
the total number of Ly-6G–positive cells had increased by∼65%
(figure 6B) ( ). In the kidney, neutrophil infiltration ap-P ! .05
peared to peak at 24 h after SubAB injection (figure 6A). Num-
bers of Ly-6G–positive cells were 5.5- and 2.9-fold higher than
those of control tissue at 24 and 48 h, respectively (figure 6B)
( and , respectively). Significant infiltration wasP ! .05 P ! .01
not observed in either the brain or the ileum (data not shown).
Apoptosis. Induction of apoptosis in tissues by SubAB was
assessed using the TUNEL assay (figure 7). In the spleen, in-
creased TUNEL-positive leukocyte counts (mainly lymphocytes
and neutrophils) were seen at 24 h after injection, relative to
numbers in control mice. Mean numbers of TUNEL-positive
cells per high-power field were and , re-41.4 7.3 6.25 1.28
spectively ( ). In the kidney, increased tubule apoptosisP ! .01
was apparent at 48 h, with TUNEL-positive cells8.5 1.26
per low-power field, compared with for control tis-3.0 0.47
sue ( ). In the liver, increased numbers of TUNEL-pos-P ! .01
itive hepatocytes were seen at 24 h ( per low-power13.7 1.48
field, compared with for control tissue; ).3.0 0.94 P ! .01
Experiments using a nontoxic SubAB derivative. The
SubAB used in these studies was purified from recombinant E.
coli; therefore, some of the observed effects might be due to
contamination with lipopolysaccharide (LPS). Additional mice
were therefore injected ip with 5 mg of a mutant derivative of
SubAB (designated SubAA272B) that had been purified using an
identical protocol. SubAA272B has a Ser272rAla mutation in the
A subunit that completely abolishes serine protease activity and
cytotoxicity for Vero cells [5, 10]. Leukocyte and platelet num-
bers were monitored in tail blood before and 24 or 48 h after
injection (figure 5B and 5C). Blood urea, ALT, AST, glucose
(figure 1), urine glucose, and protein (data not shown) levels
and histopathologic features (figures 2M–2R and 3I–3K) were
examined at 48 h. There was no detectable difference between
SubAA272B-treated mice and untreated mice for any of these
parameters. Therefore, the pathology induced by ip injection
of active SubAB is not due to LPS contamination and is directly
attributable to the serine protease activity of the A subunit of
the toxin.
DISCUSSION
SubAB is a potentially important bacterial virulence factor, al-
though assessment of its contribution to pathogenesis is com-
plicated, because the strains of E. coli shown thus far to produce
it also produce Stx [5, 6]. Both toxins are highly potent for
Vero cells, but their glycolipid receptor specificities and mech-
anisms of action are distinct [3, 5, 8]. Thus, the tissues affected
by the 2 toxins in vivo will be determined by their expression
of the respective receptors, whereas the biochemical properties
of the respective A subunits will determine the nature of cellular
damage. To our knowledge, this is the first systematic study of
the in vivo effects of purified SubAB in a mouse model, which
will inform future examination of the role of this emerging
toxin in human disease. Toxin was administered ip, because it
would be expected to enter the portal circulation, as would
toxin absorbed from the gut during a natural infection with
SubAB-producing STEC, thereby modeling potential systemic
effects of the toxin.
Remarkably, many of the in vivo effects observed in SubAB-
treated mice parallel those seen in human cases of STEC-as-
sociated HUS [11, 12] and in animals injected with purified
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Figure 6. Neutrophil infiltration. Cryopreserved sections of liver, spleen, and kidney tissue from control and subtilase cytotoxin (SubAB)–treated
mice (24 or 48 h after injection) were stained using immunofluorescence for the neutrophil surface marker Ly-6G (A). Scale bar, 1 mm. Ly-6G–positive
cells were also counted in at least 3 low-power fields (B). Data are mean  SE; differences between control and toxin-treated mice were analyzed
using Student’s t test. * ; ** .P ! .05 P ! .01
Stx [13–15]. Hematologically, there was evidence of microan-
giopathic hemolytic anemia, thrombocytopenia, and leukocy-
tosis. Biochemical analysis revealed elevated plasma urea levels,
indicating renal impairment. Histologic examination showed
extensive renal damage, including swollen and congested glo-
meruli and tubular epithelial cells, extensive thrombotic mi-
croangiopathy, generalized necrotic changes, and interstitial
hemorrhages. There was also evidence of neutrophil infiltration
into the kidney and induction of tubular apoptosis. In the brain,
there was extensive microvascular thrombosis in the cerebrum,
brain stem, and cerebellum, with hemorrhagic foci in the latter
2 sites. These findings raise the possibility that Stx may not be
entirely responsible for the life-threatening systemic sequelae
of gastrointestinal infections caused by STEC strains producing
both toxins. Clearly, it will be important to investigate the
pathologic effects of delivery of SubAB via the gastrointestinal
tract in future studies, in case the presence or absence of re-
ceptors in the gut affect toxin uptake and trafficking. Interest-
ingly, however, in mouse models, Stx administered systemically
causes pathology more like that seen in human HUS than does
Stx produced in situ by bacteria in the gut [1].
Notwithstanding the striking overlap between the pathology
induced by the 2 distinct toxins, SubAB elicited several addi-
tional changes that, to our knowledge, have not been previously
ascribed to Stx, either in humans or in animal models. Most
notable was the profound damage to the liver, including swollen
hepatocytes, decreased sinusoidal spaces, extensive micro-
thrombi and hemorrhagic and necrotic foci, recruitment of
neutrophils, and evidence of induction of apoptosis, as well as
elevated liver enzyme levels in plasma. SubAB treatment also
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Figure 7. Apoptosis in spleen, kidney, and liver tissue from control
and subtilase cytotoxin (SubAB)–treated mice. Apoptosis was assessed
by fluorescent TUNEL staining of cryopreserved sections from a control
mouse (A and C) and from SubAB-treated mice (after 24 h for spleen
and liver and after 48 h for kidney tissue) (B and D). Panels A and B are
low-power images; panels C and D are high-power images. Arrows in-
dicate TUNEL-positive nuclei. Scale bars, 0.01 mm.
induced profound splenic atrophy and massive redistribution
of leukocytes. The white pulp had a hollow appearance, which
may have been due to a combination of lymphocyte migration
and increased apoptosis or necrosis. HE staining revealed some
pyknotic and some karyolitic lymphocyte nuclei, whereas TU-
NEL staining also revealed increased apoptosis of neutrophils
and lymphocytes at 24 h after treatment. Increased apoptotic
cells in the spleen have also been reported in mice injected
intravenously with Stx1 or Stx2 [16].
Urine analysis also revealed evidence of proteinuria at 24 and
48 h after SubAB treatment, consistent with the renal damage
observed histopathologically, but glucosuria was not detected.
By contrast, Rutjes et al. [16] reported that mice treated with
Stx do exhibit glucosuria, albeit at later time points than those
used here, but proteinuria was not detected. As we have recently
reported [8], the mechanism of action of SubAB involves spe-
cific cleavage of the essential ER chaperone BiP. BiP’s func-
tions include mediating the correct folding of nascent secreto-
ry proteins, maintaining the permeability barrier of the ER
membrane, and targeting terminally misfolded proteins to the
Sec61 apparatus for retrotranslocation into the cytosol and deg-
radation [17, 18]. BiP plays a crucial role in the unfolded pro-
tein response as the ER stress-signaling master regulator [9]
and exhibits antiapoptotic properties through interference with
caspase activation [19–21]. SubAB cleaves BiP at a dileucine
motif in the hinge region between the ATPase and protein-
binding domains, potentially blocking many of these functions
[8]. In Vero cells, this cleavage occurs very rapidly and is com-
plete within 30 min at high toxin doses [8]. Although the
downstream effects of BiP cleavage within the cell have yet to
be fully investigated, these are likely to include ectopic accu-
mulation of misfolded proteins in the ER lumen, a massive ER
stress response, and induction of apoptosis. We have recently
detected cleavage of BiP in the livers of mice injected with
active SubAB and initiation of an unfolded protein response,
as indicated by induction of the transcription factor C/EBP
homologous protein at 24 h after injection [8]. In the present
study, we have presented evidence of increased apoptosis in the
liver, spleen, and kidney at similar times.
The multiple organ damage induced by SubAB could be a
consequence of direct effects on tissues or cells due to the
blockade of BiP function. This would be dependent on ex-
pression of the cognate receptor on the surface of such tissues
or cells, enabling uptake of the toxin. Comprehensive inves-
tigations of receptor distribution have yet to be conducted for
SubAB. Damage to tissues could also be mediated by ischemia/
hypoxia due to extensive thrombotic microangiopathy, as well
as by inflammation secondary to neutrophil infiltration, as ob-
served in the present study. A complete understanding of in
vivo tissue tropism and the mechanism whereby SubAB inflicts
organ damage in animal models will inform future investiga-
tions of its potential role in human disease. Studies are also
required to determine whether SubAB and Stx act in synergy
to induce pathology. Also, clinicians need to be aware of the
possibility of additional multiorgan complications occurring in
patients infected with STEC strains that also produce SubAB.
At present, there is little information on the global distribution
of such strains. Reference and diagnostic laboratories should
be encouraged to test existing strain collections and fresh clin-
ical isolates for the presence of the toxin genes by polymerase
chain reaction [6]. To date, the genes encoding this emerging
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toxin have been detected only in LEE-negative STEC [5, 6].
However, the genes are located on a self-transmissible mega-
plasmid [5], raising the possibility of widespread dissemina-
tion among diverse E. coli host strains or even other En-
terobacteriaceae.
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